Terence Flynn

Q: What is Terence Flynn's success rate?

Terence Flynn currently has a success rate of 78.15433144838475.

Q: What is the average return of Terence Flynn's calls?

Their stock ratings have generated an average return of 19.133050347871265.

Morgan Stanley | Healthcare

Terence Flynn is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1868 out of 4584 analysts, they have issued 56 stock ratings with a success rate of 78.15% and an average return of 19.13%.

Terence Flynn has a well-established track record, with 56 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 78.15% and an average return of 19.13%, underscoring their expertise and ability to identify winning opportunities for investors.

#1868

Out of 4584

Total Ratings

+78.15%

Success Rate

+19.13%

Average Return

Recent Ratings Analysis

ALMS

Buy

Mar 20, 2026

Target

$38.00

Current

$25.06

Performance

0.00%

Terence Flynn rated ALMS as Overweight on Mar 20, 2026, setting a price target of 38. Shares have remained stable near 25.06, leaving the 38 target still in play.

BNTX

Buy

Mar 11, 2026

Target

$134.00

Current

$89.27

Performance

-1.73%

On Mar 11, 2026, BNTX was given a Overweight rating by Terence Flynn, with a target price of 134. The stock traded sideways with a -1.73% move, keeping the bullish thesis unresolved.

VRTX

Buy

Mar 10, 2026

Target

$596.00

Current

$454.00

Performance

-9.05%

VRTX received a Overweight rating from Terence Flynn on Mar 10, 2026, aiming for 596. The rating hasn’t played out as hoped, with the stock trading 9.05% below expectations.

LLY

Buy

Feb 05, 2026

Target

$1313.00

Current

$906.59

Performance

-11.19%

On Feb 05, 2026, Terence Flynn published a Overweight outlook on LLY, with a target of 1313. Market action contradicted the Buy thesis, as shares slipped to 906.59.

ABBV

Buy

Feb 05, 2026

Target

$270.00

Current

$205.07

Performance

-6.37%

Terence Flynn on Feb 05, 2026 assigned ABBV a Overweight rating, with a price target of 270. The call has struggled to gain traction, with shares losing 6.37%.

AMGN

Hold

Feb 04, 2026

Target

$309.00

Current

$347.80

Performance

-5.02%

On Feb 04, 2026, Terence Flynn reaffirmed AMGN with a Equal-Weight rating, targeting 309. The Hold stance reflected market caution that was later justified.

JNJ

Buy

Jan 28, 2026

Target

$262.00

Current

$235.37

Performance

3.36%

JNJ was rated Overweight by Terence Flynn on Jan 28, 2026, with a price objective of 262. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

NRIX

Buy

Jan 08, 2026

Target

$36.00

Current

$14.43

Performance

-22.54%

On Jan 08, 2026, Terence Flynn initiated coverage on NRIX with a Overweight rating and target of 36. The Buy call has yet to be validated as shares remain 21.57 away from the target.

RCUS

Hold

Jan 08, 2026

Target

$23.00

Current

$21.64

Performance

1.36%

Terence Flynn issued a Equal-Weight recommendation for RCUS on Jan 08, 2026, price target set at 23. The rating was appropriate for a consolidating market trading near 21.64.

BHVN

Buy

Jan 06, 2026

Target

$26.00

Current

$8.93

Performance

-7.17%

On Jan 06, 2026, BHVN was evaluated by Terence Flynn, who gave a Overweight rating and target of 26. Investors saw limited payoff as shares fell short of the 26 target.

PFE

Hold

Dec 17, 2025

Target

$28.00

Current

$26.98

Performance

7.77%

Terence Flynn rated PFE as Equal-Weight on Dec 17, 2025, setting a price target of 28. Despite the Hold call, shares climbed 7.77% to 26.985, revealing unexpected momentum.

MRK

Hold

Dec 12, 2025

Target

$102.00

Current

$114.18

Performance

13.84%

On Dec 12, 2025, MRK was given a Equal-Weight rating by Terence Flynn, with a target price of 102. The stock rallied from 114.18 to 114.18 after the Hold rating, surprising to the upside.

GPCR

Buy

Dec 12, 2025

Target

$125.00

Current

$48.59

Performance

-27.54%

GPCR received a Overweight rating from Terence Flynn on Dec 12, 2025, aiming for 125. The rating hasn’t played out as hoped, with the stock trading 27.54% below expectations.

BMY

Sell

Dec 12, 2025

Target

$37.00

Current

$57.48

Performance

9.67%

On Dec 12, 2025, Terence Flynn published a Underweight outlook on BMY, with a target of 37. Investors who followed the Sell rating avoided losses as the stock weakened.

OGN

Hold

Nov 11, 2025

Target

$9.00

Current

$6.03

Performance

-19.81%

Terence Flynn on Nov 11, 2025 assigned OGN a Equal-Weight rating, with a price target of 9. The call successfully avoided chasing as shares lost 19.81%.

RPRX

Buy

Oct 10, 2025

Target

$54.00

Current

$45.36

Performance

25.97%

On Oct 10, 2025, Terence Flynn reaffirmed RPRX with a Overweight rating, targeting 54. The recommendation was supported by strong follow-through as the stock rose from 45.36 to 45.36.

UTHR

Hold

Oct 10, 2025

Target

$435.00

Current

$524.28

Performance

19.15%

UTHR was rated Equal-Weight by Terence Flynn on Oct 10, 2025, with a price objective of 435. Despite caution, upside momentum rewarded risk-takers with gains to 524.28.

ARVN

Hold

Mar 13, 2025

Target

$12.00

Current

$10.94

Performance

27.95%

On Mar 13, 2025, Terence Flynn initiated coverage on ARVN with a Equal-Weight rating and target of 12. The Hold stance underestimated the stock’s strength as it gained 27.95%.

CRSP

Sell

Feb 14, 2025

Target

$32.00

Current

$46.24

Performance

-7.00%

Terence Flynn issued a Underweight recommendation for CRSP on Feb 14, 2025, price target set at 32. The Sell call exposed risks of betting against momentum, as the stock rallied -7.00%.

NTLA

Hold

Jan 27, 2025

Target

$11.00

Current

$12.84

Performance

21.71%

On Jan 27, 2025, NTLA was evaluated by Terence Flynn, who gave a Equal-Weight rating and target of 11. Investors who stayed in despite the Hold saw upside of 21.71%.

BPMC

Buy

May 06, 2024

Target

$168.00

Current

$129.46

Performance

21.84%

Terence Flynn rated BPMC as Buy on May 06, 2024, setting a price target of 168. The call has proven timely, with shares rising 21.84% toward the price target of 168.

Frequency Asked Questions

Who is Terence Flynn?

Terence Flynn is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Terence Flynn's success rate?

Terence Flynn currently has a success rate of +78.15%.

How many ratings has Terence Flynn issued?

Terence Flynn has issued 56 stock ratings so far.

What is the average return of Terence Flynn's calls?

Their stock ratings have generated an average return of +19.13%.

What is Terence Flynn's ranking?

Terence Flynn is ranked #1868 out of 4584 analysts.

What types of ratings does Terence Flynn give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Terence Flynn?

You can follow Terence Flynn by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Terence Flynn?

Their latest rating was a Buy on ALMS issued on 2026-03-20.